PRGO:NYE-Perrigo Company PLC (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 25.35

Change

-0.06 (-0.24)%

Market Cap

N/A

Volume

2.41M

Analyst Target

USD 57.88
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+0.09 (+0.05%)

USD 85.62B
RDY Dr. Reddy’s Laboratories Ltd..

-59.38 (-80.25%)

USD 63.63B
TAK Takeda Pharmaceutical Co Ltd A..

+0.17 (+1.21%)

USD 44.45B
HLN Haleon plc

+0.01 (+0.10%)

USD 43.99B
CTLT Catalent Inc

-0.21 (-0.36%)

USD 10.78B
ELAN Elanco Animal Health

+0.11 (+0.88%)

USD 6.18B
BHC Bausch Health Companies Inc

+0.43 (+4.64%)

USD 3.56B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.16 (-1.90%)

USD 2.55B
CPHI China Pharma Holdings Inc

-0.01 (-3.80%)

USD 4.03M
YCBD cbdMD Inc

-0.01 (-2.17%)

USD 2.11M

ETFs Containing PRGO

FLWR:SW 15.27 % 0.00 %

N/A

N/A
ION Proshares S&P Global Core.. 3.96 % 0.00 %

+0.86 (+0.29%)

USD 2.90M
M7ES:XETRA HANetf ICAV - Sprott Ener.. 3.37 % 0.00 %

+0.01 (+0.29%)

USD 4.70M
UDIV:XETRA Global X SuperDividend UC.. 1.25 % 0.00 %

+0.01 (+0.29%)

USD 3.03M
SDIV:SW Global X SuperDividend UC.. 1.25 % 0.00 %

+0.02 (+0.29%)

USD 0.17B
GNRX 0.00 % 0.55 %

N/A

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

+0.19 (+0.29%)

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

+0.36 (+0.29%)

N/A
ISRL:LSE 0.00 % 0.00 %

N/A

N/A
TASE:LSE 0.00 % 0.00 %

N/A

N/A
QDVM:F 0.00 % 0.00 %

N/A

N/A
QDVM:XETRA 0.00 % 0.00 %

N/A

N/A
WSRD:CA Wealthsimple Developed Ma.. 0.00 % 0.00 %

+0.04 (+0.29%)

CAD 0.71B
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
HLIT:CA Global X Lithium Producer.. 0.00 % 0.00 %

+0.15 (+0.29%)

CAD 0.01B
BLUM:F 0.00 % 0.00 %

N/A

N/A
SDIP:LSE Global X SuperDividend UC.. 0.00 % 0.00 %

N/A

USD 0.17B
SDIU:LSE Global X SuperDividend UC.. 0.00 % 0.00 %

+0.05 (+0.29%)

USD 0.49M

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.22% 20% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.22% 20% F 20% F
Trailing 12 Months  
Capital Gain -14.42% 20% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.42% 20% F 19% F
Trailing 5 Years  
Capital Gain -49.07% 43% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.07% 43% F 16% F
Average Annual (5 Year Horizon)  
Capital Gain -12.96% 13% F 4% F
Dividend Return -10.62% 13% F 5% F
Total Return 2.34% 80% B- 54% F
Risk Return Profile  
Volatility (Standard Deviation) 8.14% 100% F 82% B
Risk Adjusted Return -130.44% 7% C- N/A F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector